These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 34091677)

  • 41. Ductal Carcinoma In Situ with Microinvasion on Core Biopsy: Evaluating Tumor Upstaging Rate, Lymph Node Metastasis Rate, and Associated Predictive Variables.
    Phantana-Angkool A; Voci AE; Warren YE; Livasy CA; Beasley LM; Robinson MM; Hadzikadic-Gusic L; Sarantou T; Forster MR; Sarma D; White RL
    Ann Surg Oncol; 2019 Nov; 26(12):3874-3882. PubMed ID: 31342378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ.
    Kurniawan ED; Rose A; Mou A; Buchanan M; Collins JP; Wong MH; Miller JA; Mann GB
    Arch Surg; 2010 Nov; 145(11):1098-104. PubMed ID: 21079099
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Value of sentinel lymph node biopsy in breast ductal carcinoma in situ upstaged to invasive carcinoma.
    Sakr R; Antoine M; Barranger E; Dubernard G; Salem C; Daraï E; Uzan S
    Breast J; 2008; 14(1):55-60. PubMed ID: 18186866
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
    Elshof LE; Tryfonidis K; Slaets L; van Leeuwen-Stok AE; Skinner VP; Dif N; Pijnappel RM; Bijker N; Rutgers EJ; Wesseling J
    Eur J Cancer; 2015 Aug; 51(12):1497-510. PubMed ID: 26025767
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?
    Harowicz MR; Saha A; Grimm LJ; Marcom PK; Marks JR; Hwang ES; Mazurowski MA
    J Magn Reson Imaging; 2017 Nov; 46(5):1332-1340. PubMed ID: 28181348
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of breast MRI in women eligible for breast conservation surgery and intra-operative radiation therapy.
    Paudel N; Bethke KP; Wang LC; Strauss JB; Hayes JP; Donnelly ED
    Surg Oncol; 2018 Mar; 27(1):95-99. PubMed ID: 29549911
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).
    Hwang ES; Hyslop T; Lynch T; Frank E; Pinto D; Basila D; Collyar D; Bennett A; Kaplan C; Rosenberg S; Thompson A; Weiss A; Partridge A
    BMJ Open; 2019 Mar; 9(3):e026797. PubMed ID: 30862637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mucocele-Like Lesions of the Breast: Rate of Upstaging and Cancer Development.
    Gibreel WO; Boughey JC
    Ann Surg Oncol; 2016 Nov; 23(12):3838-3842. PubMed ID: 27364498
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Papillary lesions on core breast biopsy: excisional biopsy for all patients?
    McGhan LJ; Pockaj BA; Wasif N; Giurescu ME; McCullough AE; Gray RJ
    Am Surg; 2013 Dec; 79(12):1238-42. PubMed ID: 24351348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Atypical Ductal Hyperplasia and Those Bordering on Ductal Carcinoma In Situ Should Be Included in the Active Surveillance Clinical Trials.
    Khoury T; Jabbour N; Peng X; Yan L; Quinn M
    Am J Clin Pathol; 2020 Jan; 153(1):131-138. PubMed ID: 31602455
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Significance of Removing Comedonecrosis as an Exclusion Criterion in Mammary Low-Risk Ductal Carcinoma In Situ Managed in an Active Surveillance Clinical Trial.
    Zhan H; Quinn M; Tian W; Yan L; Khoury T
    Am J Clin Pathol; 2021 Sep; 156(4):596-606. PubMed ID: 33769445
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors associated with upstaging of ductal carcinoma in situ diagnosed by core needle biopsy using imaging guidance.
    Wiratkapun C; Patanajareet P; Wibulpholprasert B; Lertsithichai P
    Jpn J Radiol; 2011 Oct; 29(8):547-53. PubMed ID: 21927996
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.
    Takada K; Kashiwagi S; Asano Y; Goto W; Morisaki T; Takahashi K; Fujita H; Takashima T; Tomita S; Hirakawa K; Ohira M
    BMC Cancer; 2020 Jun; 20(1):513. PubMed ID: 32493410
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is conservative management of ductal carcinoma in situ risky?
    Zheng L; Gökmen-Polar Y; Badve SS
    NPJ Breast Cancer; 2022 Apr; 8(1):55. PubMed ID: 35484283
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Implications of New Lumpectomy Margin Guidelines for Breast-Conserving Surgery: Changes in Reexcision Rates and Predicted Rates of Residual Tumor.
    Merrill AL; Coopey SB; Tang R; McEvoy MP; Specht MC; Hughes KS; Gadd MA; Smith BL
    Ann Surg Oncol; 2016 Mar; 23(3):729-34. PubMed ID: 26467458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is Sentinel Lymph Node Biopsy Necessary for Ductal Carcinoma In Situ Patients Undergoing Mastectomy?
    Miller-Ocuin JL; Howard-McNatt M; Levine EA; Chiba A
    Am Surg; 2020 Aug; 86(8):955-957. PubMed ID: 32862671
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features?
    Shi B; Grimm LJ; Mazurowski MA; Baker JA; Marks JR; King LM; Maley CC; Hwang ES; Lo JY
    Acad Radiol; 2017 Sep; 24(9):1139-1147. PubMed ID: 28506510
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ.
    Wilkie C; White L; Dupont E; Cantor A; Cox CE
    Am J Surg; 2005 Oct; 190(4):563-6. PubMed ID: 16164920
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prolonged Time from Diagnosis to Breast-Conserving Surgery is Associated with Upstaging in Hormone Receptor-Positive Invasive Ductal Breast Carcinoma.
    Hills N; Leslie M; Davis R; Crowell M; Kameyama H; Rui H; Chervoneva I; Dooley W; Tanaka T
    Ann Surg Oncol; 2021 Oct; 28(11):5895-5905. PubMed ID: 33748899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.